InvestorsObserver is giving Neubase Therapeutics Inc (NBSE) an Analyst Rating Rank of 67, meaning NBSE is ranked higher by analysts than 67% of stocks. The average price target for NBSE is $17.25 and analyst’s rate the stock as a Hold
Why are Analyst Ratings Important?
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Neubase Therapeutics Inc Stock Today?
Neubase Therapeutics Inc (NBSE) stock has fallen -11.81% while the S&P 500 has risen 0.06% as of 2:49 PM on Thursday, May 6. NBSE is lower by -$0.68 from the previous closing price of $5.76 on volume of 420,425 shares. Over the past year the S&P 500 is higher by 46.40% while NBSE is lower by -36.42%. NBSE lost -$0.81 per share the over the last 12 months.
Click Here to get the full report on Neubase Therapeutics Inc (NBSE) Stock.